Monrol Is Partnering With Telix Pharmaceuticals, Supplying Lutetium nca Lu 177 for the Manufacturing of Clinical Doses for the Phase II STARLITE 2 Study At MSK and Manufacturing Clinical Doses for Telix’s Phase III ZIRCON Trial
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced that the first patient has been dosed in the ‘STARLITE 2’ Phase II study of Telix Pharmaceuticals Limited (Telix) investigational renal cancer therapy product, TLX250 (177Lu-DOTA-girentuximab), at Memorial Sloan Kettering Cancer Center (MSK) in New York. Monrol supplied Lutetium (Lu-177 n.c.a) to Telix Pharmaceuticals to manufacture clinical doses of TLX250 for STARLITE 2 Phase II study. This collaboration may offer significant opportunities for clear cell renal cell carcinoma (ccRCC) patients in the future.
The STARLITE 2 Phase II study (NCT05239533) will assess the efficacy of TLX250 targeted radiation in combination with the anti-PD-11 immunotherapy Opdivo®2 (nivolumab) for ccRCC, the most common and aggressive form of kidney cancer. The primary endpoint is to determine the safety and efficacy of combination therapy with TLX250 as assessed by the tumours responding to the Telix therapy versus the current standard of care alone. TLX250 targets carbonic anhydrase IX (CA9),3 a protein that is highly expressed in patients that are likely to demonstrate a more limited response to cancer immunotherapy.4 The concept is that low doses of targeted radiation can potentially overcome immune resistance – or “immune prime” a tumour and therefore make it more responsive to cancer immunotherapy. Telix’s investigational companion imaging agent TLX250-CDx (89Zr-DFO-girentuximab) will also be used in the study to image CA9 expression.
Clinical doses of Telix’s investigational renal cancer companion imaging agent TLX250-CDx (89Zr-DFO-girentuximab) is also produced by Eczacıbası Monrol in its Istanbul facility for the Phase III ZIRCON clinical trial.
ZIRCON Phase III study (“Zirconium Imaging in Renal Cancer Oncology”) is an international multi-centre study at 34 sites in Europe, Australia, Turkey, Canada, and the United States. The study enrolled 30 patients in Turkey. The objective of the ZIRCON trial is to evaluate the sensitivity and specificity of PET/CT imaging with TLX250-CDx to non-invasively detect ccRCC in patients with indeterminate renal masses in comparison with surgical resection (histology), as the standard of truth.
Monrol is a company developing, manufacturing, and distributing world-class radiopharmaceutical products, radioisotopes to improve quality of life of cancer patients globally and one of the few producers of Lutetium-177 n.c.a, having uninterrupted worldwide supply capabilities. Monrol Lu-177 n.c.a production process is an exclusive processing technology having cleaner and safer production method with stable isotope enrichment capability.
"Lu-177 n.c.a contributes to our mission to improve quality of life of cancer patients globally. Our new GMP certified facility exclusively designed for theranostic R&D and production with cutting edge technology will enable us to maximize supply of high-quality Lutetium worldwide. We are committed to working closely with Telix to potentially bring new therapeutic radiopharmaceutical agents into market soon to improve patients’ lives having life threatening diseases” said Monrol General Manager Aydin Kucuk”.
Telix Chief Medical Officer, Dr. Colin Hayward noted, “The integration of precision nuclear medicine and medical oncology is underway and Telix is at the forefront of this movement to develop personalised products and patient-friendly regimens. We wish to express our gratitude to Dr. Darren Feldman and his clinical team, as well as the patients who will contribute to this ground-breaking study STARLITE 2”.
Disclosure: MSK has institutional financial interests related to Telix.
About Lutetium-177 n.c.a
Lutetium-177 n.c.a is a radioisotope of choice for targeted radionuclide therapy. Lu-177 n.c.a production process enables treatment options that have the potential to improve treatment outcomes for certain cancer patients today. Unique properties of Lutetium-177 n.c.a makes it a theranostically desirable radioisotope for peptide receptor radionuclide therapy (PRRT) to treat certain cancers like Neuro Endocrine Tumors (NET), Prostate cancer and many other clinical development programs are ongoing for other cancers like ccRCC.
In line with the company mission to create hope for a better life for cancer patients, Monrol is establishing strategic partnerships with multinational pharmaceutical companies and constructing a new production facility compliant with FDA 21 CFR Part 211 quality standards which will have an annual production capacity of 60 thousand doses. With its location close to Istanbul, a major transportation hub, the new facility will benefit from a worldwide logistics network and agreements with cargo services to 320 destinations worldwide.
About TLX250
TLX250 (177Lu-DOTA-girentuximab) is an antibody-based therapeutic platform that targets carbonic anhydrase IX (CA9), a cell surface protein that is highly expressed in several human cancers including ccRCC. High CA9 tumour expression is generally correlated with poor prognosis.
About TLX250-CDx
TLX250-CDx (89Zr-girentuximab) is being developed by Telix for the purpose of determining whether “indeterminate renal masses”, typically identified based on CT or MRI imaging, are either clear cell renal cell cancer (ccRCC) or non-ccRCC, using Positron Emission Tomography (PET) imaging. Girentuximab is a monoclonal antibody that targets carbonic anhydrase IX (CAIX), a cell surface target that is highly expressed in several human cancers including renal, lung and oesophageal cancers. In July 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy (BT) designation for TLX250-CDx, reflecting the significant unmet clinical need to improve the diagnosis and staging of ccRCC, the most common and aggressive form of kidney cancer. Telix’s companion investigational diagnostic imaging agent TLX250-CDx (89Zr-DFO-girentuximab) is the subject of a global Phase III trial recruiting (ZIRCON trial, NCT03849118).
About Monrol
Monrol is one of the world’s largest nuclear medicine companies leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals having headquarters in Istanbul. Monrol is distributing its world-class radiopharmaceutical products portfolio with excellence in global markets. Monrol is a CDMO, providing early development support to its customers as well as offering fully integrated services for today’s nimble, lean, virtual companies effectively taking new product concepts into clinical trials, demonstrating proof of concept and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment with its radiopharmaceutical products portfolio distributing to more than 50 countries around the globe. To learn more, visit www.monrol.com and LinkedIn.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
Telix’s lead product, gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection for prostate cancer imaging, has been approved by the U.S. Food and Drug Administration (FDA),5 and by the Australian Therapeutic Goods Administration (TGA).6 Telix is also progressing marketing authorisation applications for this investigational candidate in Europe7 and Canada.8
1 Programmed cell death protein 1.
2 Opdivo is a registered trade mark of Bristol Myers Squibb.
3 Carbonic anhydrase IX.
4 Giatromanolaki et al. British Journal of Cancer. 2020.
5 ASX disclosure 20 December 2021.
6 ASX disclosure 2 November 2021.
7 ASX disclosure 10 December 2021.
8 ASX disclosure 16 December 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005820/en/
Contact information
Mr. Aydın Küçük
General Manager
monrol@monrol.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Partners with Cailabs to Test Next-Generation Laser Communication Technology15.9.2025 11:00:00 EEST | Press release
SES, a leading space solutions company, announced today it will test new optical ground stations built by France-based Cailabs to send data from space using laser beams instead of radio waves. By using optical communication, SES expects to be able to boost data transmission speeds, provide more secure links, and help alleviate congestion in increasingly crowded radio frequency bands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915922379/en/ SES Partners with Cailabs to Test Next-Generation Laser Communication Technology. Credit: Cailabs The partnership marks a major step forward for optical communications, which use light beams to transmit data at speeds of up to 10 gigabits per second—about 100 times faster than typical home internet. Unlike traditional radio signals, laser beams are nearly impossible to intercept or jam, making them ideal for secure government and business communications. The biggest challenge with o
Prometheus Slashes Cost of Carbon Capture by More Than 80%, Unlocking Affordable E-Fuels as a New Source of 24/7 Carbon Neutral Power15.9.2025 11:00:00 EEST | Press release
Prometheus Fuels (Prometheus), the company producing low-cost carbon neutral fuels from direct air capture and renewable electricity, today announced it has achieved the lowest-cost carbon capture in the world, reducing the cost of Direct Air Capture (DAC) by more than 80 percent compared to industry averages. At under $50 per ton, Prometheus’ DAC cost breakthrough unlocks carbon neutral fuels at fossil fuel prices, without relying on subsidies, biogenic carbon, or point-source emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915079297/en/ Prometheus builds a 200-ton-per-year Direct Air Capture system at its California HQ, adding capacity to its currently operating 16-TPY system, the world’s lowest-cost DAC technology at less than $50 per ton CO₂. The achievement is demonstrated in Prometheus’ new 200-ton-per-year DAC system, currently under construction and scheduled for completion this year. The system captures
LSEG Launches Digital Markets Infrastructure Platform for Private Funds, and Facilitates First Transaction15.9.2025 10:25:00 EEST | Press release
LSEG today announces that it has launched its Digital Markets Infrastructure (“DMI”) platform for private funds and facilitated its first transaction. DMI, which is powered by Microsoft Azure, will deliver blockchain-powered scale and efficiencies for the full asset lifecycle – from issuance, tokenisation and distribution to post trade asset settlement and servicing, across multiple asset classes. LSEG will ensure that this platform is interoperable with current market solutions in distributed ledger technology as well as traditional finance, fully utilising a range of the group's products and services, including Workspace. Developed in collaboration with Microsoft, DMI is aligned with LSEG’s goal of being the first global exchange group to support customers across the full funding continuum, alongside other group initiatives such as the Private Securities Market. Private funds is the first asset class to benefit from the DMI platform, with expansion to additional asset classes planned
Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 202515.9.2025 10:15:00 EEST | Press release
DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose biosensing technology for people with all types of diabetes at the upcoming 61st annual European Association for the Study of Diabetes (EASD) Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915690916/en/ Findings will demonstrate how CGM can reduce neonatal complications linked to gestational diabetes more effectively than fingersticks. “Each year, EASD provides a high-profile opportunity to highlight our latest product innovations and new clinical data that demonstrates how Dexcom glucose biosensing technology can empower people with all types of diabetes across the globe to take control of their health, while reinforcing Dexcom CGM as a cost-effective solution for diabetes management,” said Jake Leach, president and chief operating offic
Komoot Unveils Modern Design as Part of Ambitious Product Roadmap15.9.2025 10:00:00 EEST | Press release
Komoot, the leading outdoor app, is rolling out a fresh new design: The experience is currently live for Web users worldwide, with Mobile slated for release by the end of September. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915468295/en/ The updated design—the first in a series of major initiatives outlined within komoot’s ambitious new roadmap—introduces a refreshed look and includes significant improvements to the user journey to deliver a more intuitive and enjoyable experience overall. At the same time, komoot’s core navigation and workflows remain the same: The result is a modern, intuitive design that still feels familiar to returning users. The most notable changes include: A contemporary design. The new look introduces several refreshed design elements—such as color palette, fonts, icons, and illustrations—to elevate and modernize the overall komoot brand and user experience. A clearer and more intuitive stru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom